Table 1 Baseline characteristics of the 84 study participants
Baseline patient characteristics | N (%) or Median [IQR] |
|---|---|
Demographics | |
Age, years | 64 [50–69.8] |
Male | 47 (56) |
Body mass index | 24 [21.6–27] a |
General health | |
Charlson Comorbidity Index | 4 [2–5] |
ECOG Performance Status | 1 [0–1.25] |
0 | 21 (25) |
1–2 | 56 (66.7) |
3–4 | 7 (8.3) |
Clinical Frailty Scale score | 2 [2–4] |
Haematological malignancy | |
Diffuse large B-cell lymphoma | 54 (64.3) |
Other lymphoma | 16 [19] |
B-cell acute lymphoblastic leukaemia | 8 (9.5) |
Multiple myeloma | 6 (7.1) |
Time from hematological diagnosis to CAR-T therapy, months | 17.6 [8.8–37.5] |
Number of chemotherapy lines before CAR-T therapy | 2.5 [2, 3] |
Autologous haematopoietic stem-cell transplantation | 18 (21.4) |
Allogeneic haematopoietic stem-cell transplantation | 8 (9.5) |
CAR-T product | |
Axicabtagene ciloleucel | 62 (73.8) |
Tisagenlecleucel | 10 (11.9) |
Brexucabtagen autoleucel | 6 (7.1) |
Idecabtagene vicleucel | 6 (7.1) |